Nascent Biotech Inc. (NBIO)

[budfoxfun]

Agree, way undervalued at these levels.

$NBIO

[pumpnass]

I’m feeling phase II is right around the corner

[budfoxfun]

Great to hear: "The presentation displayed our Phase I data, which included our safety data at various dose cohorts and early outcomes data, was well received and viewed by interested parties at the conference. In summary, it showed the drug to be very safe at 5 ascending dose cohorts and definitive bioactivity in several patients," stated Dr. Mini Gill who presented for the Company.

$NBIO

[BlazingStocks]

Love the News this morning... Looking forward to seeing how it opens.

$NBIO

[BlazingStocks]

$NBIO News June 07, 2023

Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting
https://finance.yahoo.com/news/nascent-biotech-phase-clinical-data-120000403.html

[budfoxfun]

$NBIO Premarket News! Nascent Biotech Phase I Clinical Data Presented at the American Society of Clinical Oncology Annual Meeting https://finance.yahoo.com/news/nascent-biotech-phase-clinical-data-120000403.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance

[budfoxfun]

$NBIO loading up this week, thin to .05's!

[gladeshawk]

NBIO, worth a flyer at current PPS. Just my two cents worth.

[pumpnass]

Who says this stock was abandoned? Smart people are just staying quiet and accumulating ;)

[RammageRaul]

Why was this pump abandoned lol

[jedijazz]

$NBIO could see a gap up this week on huge news.

[BlazingStocks]

Power Hour approaches and we'll see if this can break 0.058.

$NBIO - About Nascent Biotech

Nascent Biotech, Inc. is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

[budfoxfun]

$NBIO under 006 a steal here!

[BlazingStocks]

I foresee 2 PRs in the near future...on Phase I and Phase II. We're early but with a great opportunity to load cheaper shares from the impatient.

The review is required for approval to commence the next phase in the development of Pritumumab ("PTB"). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA.

$NBIO

[jedijazz]

$NBIO Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

[BlazingStocks]

Coming up on trading half of its 10-day average volume as lunchtime continues...

$NBIO

[BlazingStocks]

Yes, 0.058s fall and next up is 0.069s. Nice volume so far today.

$NBIO

[budfoxfun]

Won't take much for .06's now!

$NBIO

[jedijazz]

$NBIO very positive sentiment on this news! #FDA #phaseII

[BlazingStocks]

It's nearly trading a third of its 10-day average volume within the 30 minutes...nice opportunity to load cheaper shares so far this morning.

$NBIO

[jedijazz]

$NBIO huge buys and buy opinion on this news.

[BlazingStocks]

Agreed a HUGE step forward...plus we should be getting News on Phase I results soon.

Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA. The Company anticipates initial comments from the FDA approximately 30 days from the date of filing.

$NBIO

[jedijazz]

Nascent Biotech, Inc. (OTCQB:NBIO) announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval.
The review is required for approval to commence the next phase in the development of Pritumumab ("PTB"). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA. The Company anticipates initial comments from the FDA approximately 30 days from the date of filing.


About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

[pumpnass]

This is a huge milestone! Fingers crossed

[BlazingStocks]

WOW, great News from Nascent. We knew that this was coming soon...

$NBIO News April 18, 2023

Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
https://finance.yahoo.com/news/nascent-submits-phase-2-clinical-120000457.html

[budfoxfun]

Huge Premarket News! $NBIO April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab ("PTB"). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA. The Company anticipates initial comments from the FDA approximately 30 days from the date of filing.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

[budfoxfun]

Huge news there jedi!

$NBIO

[jedijazz]

NEWS: Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
Nascent Biotech Inc.
Tue, April 18, 2023 at 8:00 AM EDT·1 min read

Nascent Biotech Inc.
In this article: NBIO

NORTH PALM BEACH, FL / ACCESSWIRE / April 18, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company whose business is focused in the brain cancer space, announced today that the Protocol for the Phase 2 clinical trials was submitted to the FDA for review and approval. The review is required for approval to commence the next phase in the development of Pritumumab ("PTB"). Data related to Phase 1 Clinical Research evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has also been submitted to the FDA. The Company anticipates initial comments from the FDA approximately 30 days from the date of filing.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers and viral infections, helping people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer.

For further information please visit our website www.nascentbiotech.com.

Forward Looking Safe Harbor Statement

Statements in this press release about our future expectations constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Corporate Contact
Sean Carrick | CEO | Nascent Biotech, Inc.
[e-mail]

Public Relations
EDM Media, LLC
https://edm.media
[phone]

SOURCE: Nascent Biotech Inc.



View source version on accesswire.com:
https://www.accesswire.com/749560/Nascent-Submits-Phase-2-Clinical-Research-Protocol-to-FDA-for-Review-and-Approval

[budfoxfun]

Adding this week!

$NBIO

[BlazingStocks]

Phase II will be another level of confidence in the Phase I results by the company and the FDA.

Nascent pledges to continue to collect and evaluate the Clinical data from the Phase I trial while readying its submission to the U.S. FDA for Phase II consideration.

$NBIO

[budfoxfun]

Agree, a must own at these levels, way undervalued!

$NBIO

[BlazingStocks]

Thankfully, for $NBIO shareholders, PTB recently completed its landmark Phase I trial. The company is now working with the FDA to quickly line up Phase II research, where the rubber really meets the road.

As noted in its most recent release, its Phase I clinical trial evaluating safety and tolerance for PTB as a treatment for Primary and Metastatic Brain Cancers has been completed, and Nascent pledges to continue to collect and evaluate the Clinical data from the Phase I trial while readying its submission to the U.S. FDA for Phase II consideration.

[BlazingStocks]

Phase II is a HUGE milestone for the company.

$NBIO

[budfoxfun]

$NBIO Vies for Phase II Kick-Off After 8yr Journey with Unique Cancer Treatment https://www.marketwatch.com/press-release/nbio-vies-for-phase-ii-kick-off-after-8yr-journey-with-unique-cancer-treatment-2023-03-21?reflink=mw_share_twitter

[budfoxfun]

Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration.

Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. Phase I reinforced the companies' determination and excitement around this unique monoclonal antibody treatment approach and Phase I has shown that it can be given safely at high doses. This is a new pathway toward attacking one of the defining health challenges we face, with longer-term implications that transcend the brain cancer market. We look forward to the opportunity to see our unique R&D platform become a game changer for patients suffering from brain cancer.

$NBIO

[Aa5]

Apologies, I posted prior message on wrong board

[Aa5]

When trading is allowed, could someone please post this on iHub?

[BlazingStocks]

Just under the new high of the day set during this Power Hour...with the ability to make another one in the last few minutes.

$NBIO trading strong!

[BlazingStocks]

A new high of the day is still possible in the last half of Power Hour... nice volume on the News today.

Nascent Announces the Completion of Its Phase1 Clinical Trials
https://finance.yahoo.com/news/nascent-announces-completion-phase1-clinical-130000007.html

$NBIO

[Robertscott]

Getting better by the hour NBIO

[Robertscott]

HOD heading into power hour NBIO

[BlazingStocks]

Nice continuous action today. It's trading nearly 45% of its 10-day average volume... UP 30%, at the high of the day, and a new high of the day on the ASK.

$NBIO

[budfoxfun]

$NBIO +30% nice push this afternoon!

[BlazingStocks]

Loving how it's trading so far this morning, good volume, UP 20%, and at the high of the day.

$NBIO

[BlazingStocks]

It's trading a third of its 10-day average volume within the first 45 minutes of the day... On News, UP almost 11%.

$NBIO

[Robertscott]

Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. NBIO

[BlazingStocks]

Absolutely and more updates forthcoming...

Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration.

$NBIO

[Robertscott]

This is a major step for NBIO

[budfoxfun]

Nascent will continue to collect and evaluate the Clinical data from the Phase I trial as it prepares to submit results to the U.S. FDA for Phase II consideration.

Completing the Phase I trial is a major milestone and Nascent is excited to move toward finalizing plans for Phase II research. Phase I reinforced the companies' determination and excitement around this unique monoclonal antibody treatment approach and Phase I has shown that it can be given safely at high doses. This is a new pathway toward attacking one of the defining health challenges we face, with longer-term implications that transcend the brain cancer market. We look forward to the opportunity to see our unique R&D platform become a game changer for patients suffering from brain cancer.

PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells.

$NBIO

[BlazingStocks]

Sweet $NBIO News! Been waiting for this update!